Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry

American Journal of Hematology

Volumn 90, Issue 3, 2015, Pages 208-214

  Hulegårdh, Erik ^a   Nilsson, Christer ^b   Lazarevic, Vladimir ^c,d   Garelius, Hege ^a,d   Antunovic, Petar ^d,e   Rangert Derolf, Åsa ^b,d   Möllgård, Lars ^a,d   Uggla, Bertil ^d,f   Wennström, Lovisa ^a,d   Wahlin, Anders ^d,g   Höglund, Martin ^d,h   Juliusson, Gunnar ^c,d   Stockelberg, Dick ^a,d   Lehmann, Sören ^b,d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Swedish Acute Myeloid Leukemia Group   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^g UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^h UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; IDARUBICIN; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; GENETIC RISK; HUMAN; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; AGE; BREAST NEOPLASMS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MORTALITY; NEOPLASMS, SECOND PRIMARY; PALLIATIVE THERAPY; PATHOLOGY; PROGNOSIS; REGISTER; REMISSION; RISK FACTOR; SURVIVAL; SWEDEN; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PALLIATIVE CARE; PROGNOSIS; REGISTRIES; REMISSION INDUCTION; RISK FACTORS; SURVIVAL ANALYSIS; SWEDEN;

EID: 84923114820     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23908     Document Type: Article

References (25)

1. Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol 2007;20:29-37.
2. Ostgard LS, Kjeldsen E, Holm MS, et al. Reasons for treating secondary AML as de novo AML. Eur J Haematol 2010;85:217-226.
3. Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. Haematologica 1999;84:937-945.
4. Pulsoni A, Pagano L. Treatment of secondary acute myeloid leukemia. J Clin Oncol 2005;23:926-927.
5. Rizzieri DA, O'Brien JA, Broadwater G, et al. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer 2009;115:2922-2929.
6. Stolzel F, Pfirrmann M, Aulitzky WE, et al. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: Results of the prospective AML96 trial. Leukemia 2011;25:420-428.
7. Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137-2145.
8. Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120-125.
9. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179-4187.
10. Lazarevic V, Horstedt AS, Johansson B, et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: The Swedish population-based experience. Blood Cancer J 2014;4:e188.
11. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-365.
12. Wahlin A, Billstrom R, Bjor O, et al. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Eur J Haematol 2009;83:99-107.
13. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: A population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011;25:1128-1134.
14. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ 2009;338:b2393.
15. Harrell FE Jr. wcfCDamo. Hmisc: Harrell Miscellaneous. R package version 310-11 2013.
16. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
17. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013.
18. Pagana L, Pulsoni A, Tosti ME, et al. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol 2001;112:109-117.
19. Preiss BS, Bergmann OJ, Friis LS, et al. Cytogenetic findings in adult secondary acute myeloid leukemia (AML): Frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML. Cancer Genet Cytogenet 2010;202:108-122.
20. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320.
21. Schoch C, Schnittger S, Klaus M, et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: Incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003;102:2395-2402.
22. Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009;145:598-605.
23. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program 2009;2009:385-395.
24. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992;19:47-84.
25. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 2003;102:43-52.